Anti-MHC monoclonal antibodies

Drug Profile

Anti-MHC monoclonal antibodies

Alternative Names: Anti-MHC; Anti-MHC class I monoclonal antibody; Anti-MHC class II monoclonal antibody; Anti-MHC monoclonal antibody

Latest Information Update: 25 Sep 2002

Price : $50

At a glance

  • Originator Nonindustrial source; Yamaguchi University
  • Developer Nonindustrial source
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Graft-versus-host disease; Transplant rejection

Most Recent Events

  • 12 Aug 1998 A preclinical study has been added to the Transplant rejection pharmacodynamics section
  • 13 Oct 1995 An in vivo study has been added to the Transplant rejection pharmacodynamics section
  • 23 Mar 1995 Preclinical development for Graft-versus-host disease in USA (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top